Chinook Therapeutics
Clinical-stage biopharmaceutical company focused on developing precision medicines for kidney diseases. Acquired by Novartis in 2023 for $3.5 billion.
Website
https://www.chinooktx.comLocation
Seattle, Washington & Vancouver, British Columbia
Founded
2019
Investors
1
Categories
biotech, nephrology, kidney-disease, therapeutics, autoimmune
Notes
Chinook Therapeutics was a clinical-stage biopharmaceutical company dedicated to developing precision medicines for kidney diseases, including IgA nephropathy and other serious kidney conditions. The company was formed through the merger of Chinook Therapeutics and Aduro Biotech in 2020.
In August 2023, Novartis acquired Chinook Therapeutics for approximately $3.5 billion, gaining access to Chinook's kidney disease pipeline, including atrasentan and zigakibart (BION-1301).
Team (Pre-Acquisition)
- Eric Dobmeier - Former President & Chief Executive Officer
- LinkedIn: linkedin.com/in/ericdobmeier
- Andrew King, M.D. - Former Chief Medical Officer
Additional Research Findings
- Acquired by Novartis in August 2023 for $3.5 billion
- Former NASDAQ: KDNY (now delisted)
- Formed through merger with Aduro Biotech in 2020
- Lead programs: atrasentan (IgA nephropathy), zigakibart
- Focus on precision medicine for kidney diseases
- Seattle, Washington and Vancouver, British Columbia offices
- Pipeline now part of Novartis nephrology portfolio
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apple Tree Partners | New York, USA | biotech-focused | series-aseries-b+2 | 23 |